Fundings in medical technology for the month of July 2014 have reached $364 million, led by the Intersect ENT $55 million IPO and fundings of Advanced Cell Technology ($30 million), Rotation Medical ($27 million) and Amedica Corp. ($26 million). Below are the top fundings thus far in the month.
Intersect ENT, Inc., has raised $55 million in an initial public offering according to the company
Drug-eluting sinus implant
Advanced Cell Technology, Inc., has raised $30 million in an equity round of funding according to the company
Human embryonic stem cell and adult stem cell for a range of treatments, including macular degeneration
Rotation Medical, Inc., has raised $27.2 million in a Series B round of funding according to press reports
Collage scaffold for the treatment of rotator cuff tears
Amedica Corp. has raised $26 million in debt and equity funding according to the company
Orthopedic implant materials
For an updated list of medtech fundings in July 2014, revisit this post (refresh your browser) and see link. For a full list of the fundings in medtech, by month, since 2009, see link.
Gauze dressings, bioengineered skin, alginates, negative pressure devices, cellular growth factors, hydrogels, antimicrobial dressings — all of these products (and more) represent the practice of wound management for the entire spectrum of wound types and severities. Practice patterns, regulatory requirements, price pressures, healthcare delivery system gatekeepers, demographics, cultural sensitivities — all of these, and more, combine in the forces that dictate the size and outlook of the markets for different wound management products in global markets.
It’s no surprise, then, that product sales are growing (and in some cases declining) at different rates in different regions of the world, but the data is clear on this. MedMarket Diligence researched and published this data in its global wound management market Report #S249, which details the clinical practice of wound management, the products on the market and in development, the current and forecast markets for each worldwide and regionally and the competitors vying for market presence now and in the future.
Researched from primary and secondary sources, the global wound market data illustrated above (which is also detailed by country) and presented in Report #S249, “Worldwide Wound Management, Forecast to 2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World.”
New medical technologies under development at recently identified startups span ophthalmology, gastroenterology, cardiology, spine surgery, orthopedics, patient monitoring and surgical instrumentation. Below are the technologies at the recently identified medtech startups that have been included in the Medtech Startups Database.
Intraocular lens for presbyopia.
Portable, wireless EKG device.
Tissue engineering in peripheral and central nervous system injury.
Micro transtympanic drug delivery to the ear.
Diagnosis of functional GI disorders.
Spinal implants and instrumentation systems.
Surgical suction devices.
Calcium phosphate bioceramic implants for bone defects.
Intervertebral fusion cage.
Monitoring of neural activity during sedation.
Surgical instrument positioning systems for minimally invasive and robotic surgery.
Critical care monitoring technologies.
For a historical listing of medical technologies under development at startups, see link.
Extensive research has demonstrated that wound fluid is rich in growth factors. Growth factors are naturally occurring proteins found primarily in platelets and macrophages. They are needed for normal wound healing to promote growth and migration of fibroblasts, endothelial cells and keratinocytes. The functions of growth factors include; attraction of cells to the wound site (chemotaxis), stimulation of cell division/ proliferation (mitogenic competence/progressive), differentiation of cells into specific phenotypes (transformation), and stimulation of cells to perform functions or secrete other growth factors. Growth factors bind to receptors on the cell surface where they activate cellular proliferation and/or differentiation. There are a number of growth factors which are involved in wound healing at different points in time. Many are quite versatile and capable of stimulating cellular division in different cell types; others are specific to a particular cell type.
Below is a list of the growth factors involved in wound healing:
Epidermal growth factor
Transforming growth factor-α
Hepatocyte growth factor
Vascular endothelial growth factor
Platelet derived growth factor
Fibroblast growth factor 1 and 2
Transforming growth factor-β
Keratinocyte growth factor
(The origins, effects and companies pursuing development of these growth factors are described in link.)
Since the market for growth factors in wound management is very new, there are as yet only a few players, but with compound growth in this market pushing well over 20% annually, the lucrative market will stimulate a burst of new entrants over the next few years. Currently, Smith & Nephew holds a dominant position due to its acquisition of Healthpoint Biotherapeutics (pre-acquisition market shares shown separately, below).
Additional companies include Citagenix, Cytomedix, Daewoong Pharmaceutical, Macrocure and others.
With Medtronic’s pending $42.9 billion purchase of Covidien, the company now has bought itself a seat at the global wound management table. No, this is not a “current” concern for other active wound market companies, since Covidien is not dominant a contender in wound management — the aggregate of its Covidien and Kendall branded products’ presence is a meager 6%.
However, Medtronic never settles for low market share, so it is fair to assume that Medtronic’s planned future involvement in wound management and other of Covidien’s markets is likely to be anything but the “status quo”.
If I had a nickel for every headline like this that ultimately failed, like the technology, to actually achieve the promise, I would be on a tropical beach sipping pina coladas:
“Glucose monitoring for diabetes made easy with a blood-less method” (link)
Technologies in development for less-invasive or non-invasive glucose monitoring are legion, and many are very promising, but you can’t fill out a deposit slip with these promises. Frequently, such alternatives are based on the premise of quantifying blood glucose by sensitively detecting glucose in other fluids (interstitial fluid, tears, saliva, urine, etc.) that do not require the use of lancets to draw blood. However, despite their sensitivity and other sophistication in detecting minute quantities of glucose, their “arm’s length” to actual blood glucose compounds the challenge by requiring that the test reproducibly correlate the sample values with actual, current blood glucose levels.
The challenge stands unanswered, while the burgeoning population of endlessly finger-pricked diabetics remains painfully unsatisfied.
As a practical reality, continuous blood glucose monitors like those from Dexcom and Medtronic offer far more to the diabetic population, not only by avoiding finger pricks but also by revealing the patterns in blood glucose levels over time as a result of activity, carbohydrate intake, insulin bolus, insulin basal rate, stress and countless other patient-specific determinants.